dc.contributor.author | Ngai, Lok Lam | |
dc.contributor.author | Ma, Connie Y. | |
dc.contributor.author | Maguire, Orla | |
dc.contributor.author | Do, An D. | |
dc.contributor.author | Robert, Alberto | |
dc.contributor.author | Logan, Aaron C. | |
dc.contributor.author | Griffiths, Elizabeth A. | |
dc.contributor.author | Nemeth, Michael J. | |
dc.contributor.author | Green, Cherie | |
dc.contributor.author | Pourmohamad, Tony | |
dc.contributor.author | van Kuijk, Bo J. | |
dc.contributor.author | Snel, Alexander N. | |
dc.contributor.author | Kwidama, Zinia W. | |
dc.contributor.author | Venniker-Punt, Bianca | |
dc.contributor.author | Cooper, James | |
dc.contributor.author | Manz, Markus G. | |
dc.contributor.author | Gjertsen, Bjørn Tore | |
dc.contributor.author | Smit, Linda | |
dc.contributor.author | Ossenkoppele, Gert J. | |
dc.contributor.author | Janssen, Jeroen J. W. M. | |
dc.contributor.author | Cloos, Jacqueline | |
dc.contributor.author | Sumiyoshi, Teiko | |
dc.date.accessioned | 2022-04-19T07:13:45Z | |
dc.date.available | 2022-04-19T07:13:45Z | |
dc.date.created | 2022-01-27T14:14:59Z | |
dc.date.issued | 2021 | |
dc.identifier.issn | 0902-4441 | |
dc.identifier.uri | https://hdl.handle.net/11250/2991210 | |
dc.description.abstract | Objectives
This study aims to retrospectively assess C-lectin-like molecule 1 (CLL-1) bimodal expression on CD34+ blasts in acute myeloid leukemia (AML) patients (total N = 306) and explore potential CLL-1 bimodal associations with leukemia and patient-specific characteristics.
Methods
Flow cytometry assays were performed to assess the deeper immunophenotyping of CLL-1 bimodality. Cytogenetic analysis was performed to characterize the gene mutation on CLL-1-negative subpopulation of CLL-1 bimodal AML samples.
Results
The frequency of a bimodal pattern of CLL-1 expression of CD34+ blasts ranged from 8% to 65% in the different cohorts. Bimodal CLL-1 expression was most prevalent in patients with MDS-related AML (P = .011), ELN adverse risk (P = .002), NPM1 wild type (WT, P = .049), FLT3 WT (P = .035), and relatively low percentages of leukemia-associated immunophenotypes (P = .006). Additional immunophenotyping analysis revealed the CLL-1− subpopulation may consist of pre-B cells, immature myeloblasts, and hematopoietic stem cells. Furthermore, (pre)-leukemic mutations were detected in both CLL-1+ and CLL-1− subfractions of bimodal samples (N = 3).
Conclusions
C-lectin-like molecule 1 bimodality occurs in about 25% of AML patients and the CLL-1− cell population still contains malignant cells, hence it may potentially limit the effectiveness of CLL-1-targeted therapies and warrant further investigation. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Wiley | en_US |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/deed.no | * |
dc.title | Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients | en_US |
dc.type | Journal article | en_US |
dc.type | Peer reviewed | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | Copyright 2021 Genentech Inc. European Journal of Haematology | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.doi | 10.1111/ejh.13672 | |
dc.identifier.cristin | 1991432 | |
dc.source.journal | European Journal of Haematology | en_US |
dc.source.pagenumber | 343-353 | en_US |
dc.identifier.citation | European Journal of Haematology. 2021, 107 (3), 343-353. | en_US |
dc.source.volume | 107 | en_US |
dc.source.issue | 3 | en_US |